Adam Gordon

May 20, 2024 | rand.org | Megan S. Schuler |Andrew W. Dick |Adam Gordon |Brendan Saloner

BackgroundWe examined the number and characteristics of high-volume buprenorphine prescribers and the nature of their buprenorphine prescribing from 2009 to 2018. MethodsIn this observational cohort study, IQVIA Real World retail pharmacy claims data were used to characterize trends in high-volume buprenorphine prescribers (clinicians with a mean of 30 or more active patients in every month that they were an active prescriber) during 2009–2018.

Mar 27, 2024 | bjgp.org | Adam Gordon |Lauren McCarthy |Kayla Borley |Rachael Carroll

IntroductionAround 410 000 people live in care homes in the UK.1 Care home residents are predominantly older, and live with multiple long-term conditions and one or more disability. Between 62% and 86% of residents live with cognitive impairment.2,3 Many are approaching the end of their lives.

Feb 8, 2024 | bgs.org.uk | Amit Arora |Adam Gordon

We last surveyed the BGS membership in the midst of the COVID-19 pandemic. The survey was designed to gather intelligence specifically about our members’ experiences during the pandemic – the challenges they faced and how the services they worked in were meeting these challenges. While COVID is very much still present in our healthcare systems, the emergency posed by the virus has passed. We are aware, however, that the situation faced by our members daily is still incredibly tough.

Jul 14, 2023 | rand.org | Megan S. Schuler |Brendan Saloner |Adam Gordon |Andrew W. Dick

Background Buprenorphine is a key medication to treat opioid use disorder (OUD). Since its approval in 2002, buprenorphine access has grown markedly, spurred by major federal and state policy changes. This study characterizes buprenorphine treatment episodes during 2007 to 2018 with respect to payer, provider specialty, and patient demographics.